Shares of Moderna Inc. said Friday that it asked the European Medicines Agency to authorize its COVID-19 vaccine for use in children between the ages of 6 months and 6 years old. The company also filed for authorization in this age group in the U.S. this week. Moderna separately said Friday that it plans to build an mRNA vaccine manufacturing site in Quebec. Moderna’s stock has declined 44.2% this year, while the broader S&P 500 is down 10.0%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
